Blinatumomab for relapsed/refractory Burkitt's lymphoma

Bookmark and Share
Published: 20 Jun 2019
Views: 1264
Dr Johannes Düll - University of Würzburg, Würzburg, Germany

Dr Johannes Düll speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about using blinatumomab for relapsed/refractory Burkitt's lymphoma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.